

Supplementary Materials

Supplemental Table 1. Prevalence of past-month cannabis use by sex and prevalence difference (PD) stratified by age group, NSDUH 2014-2023

Supplemental Table 2. Prevalence of past-year daily/near daily (300 or more days) cannabis use by sex and prevalence difference (PD) stratified by age group, NSDUH 2014-2023

Supplemental Table 3. Prevalence of DSM-5 cannabis use disorder by sex and prevalence difference (PD) stratified by age group, NSDUH 2014-2023

Supplemental Table 4. Estimated population counts (in thousands) by sex, age group, and cannabis use outcomes (past-month use, daily/near-daily use, and DSM-5 cannabis use disorder), NSDUH 2014–2023

Supplemental Table 1. Prevalence of past-month cannabis use by sex and prevalence difference (PD) stratified by age group, NSDUH 2014-2023

		Female	Male	Female-Male
		% (95% CI)	% (95% CI)	PD (95% CI)
Age 12-17	2014	6.7 (6.0, 7.4)	7.8 (7.1, 8.6)	-1.1 (-2.0, -0.3)
	2015	6.6 (5.8, 7.4)	7.4 (6.8, 8.1)	-0.8 (-1.8, 0.1)
	2016	5.9 (5.3, 6.6)	6.7 (6.0, 7.4)	-0.7 (-1.7, 0.3)
	2017	6.7 (5.9, 7.5)	6.4 (5.5, 7.3)	0.2 (-1.0, 1.5)
	2018	6.2 (5.3, 7.1)	6.8 (6.0, 7.6)	-0.6 (-1.7, 0.5)
	2019	7.3 (6.3, 8.3)	7.7 (6.8, 8.6)	-0.4 (-1.8, 1.0)
	2020	5.5 (4.0, 7.0)	6.2 (4.4, 7.9)	-0.7 (-3.3, 1.9)
	2021	6.6 (5.4, 7.8)	5.5 (4.3, 6.7)	1.0 (-0.6, 2.6)
	2022	7.4 (6.4, 8.4)	5.1 (4.3, 5.9)	2.3 (1.0, 3.6)
	2023	6.7 (5.6, 7.8)	5.4 (4.4, 6.5)	1.3 (-0.1, 2.7)
Age 18-25	2014	16.1 (14.7, 17.6)	23.5 (22.0, 25.1)	-7.4 (-9.4, -5.4)
	2015	16.6 (15.6, 17.6)	23.5 (22.1, 25.0)	-6.9 (-8.4, -5.4)
	2016	17.4 (16.3, 18.5)	23.9 (22.8, 25.0)	-6.5 (-8.0, -5.0)
	2017	18.7 (17.7, 19.8)	24.4 (23.1, 25.7)	-5.7 (-7.1, -4.2)
	2018	19.8 (18.6, 20.9)	24.1 (22.6, 25.5)	-4.3 (-6.0, -2.6)
	2019	21.2 (19.9, 22.6)	24.6 (23.2, 26.0)	-3.4 (-5.2, -1.6)
	2020	23.0 (20.5, 25.6)	23.6 (21.6, 25.6)	-0.5 (-3.9, 2.8)
	2021	22.8 (21.0, 24.5)	26.6 (24.1, 29.2)	-3.8 (-6.7, -1.0)
	2022	24.7 (23.0, 26.5)	27.5 (25.6, 29.4)	-2.7 (-4.8, -0.7)
	2023	23.8 (22.0, 25.5)	25.4 (23.6, 27.2)	-1.7 (-4.1, 0.8)
Age 26+	2014	4.4 (4.0, 4.8)	9.2 (8.6, 9.7)	-4.8 (-5.5, -4.0)
	2015	4.5 (4.2, 4.9)	8.6 (7.8, 9.4)	-4.0 (-4.8, -3.2)
	2016	4.9 (4.5, 5.3)	9.5 (8.9, 10.1)	-4.6 (-5.4, -3.8)
	2017	5.6 (5.1, 6.1)	10.2 (9.4, 11.0)	-4.6 (-5.6, -3.6)
	2018	6.4 (5.9, 7.0)	11.0 (10.3, 11.6)	-4.5 (-5.4, -3.7)
	2019	7.5 (6.9, 8.1)	12.9 (12.2, 13.7)	-5.5 (-6.4, -4.5)
	2020	8.7 (7.7, 9.7)	12.2 (11.2, 13.2)	-3.5 (-4.9, -2.1)
	2021	10.0 (9.2, 10.8)	14.5 (13.0, 15.9)	-4.5 (-6.0, -2.9)
	2022	11.7 (11.0, 12.4)	17.1 (16.1, 18.1)	-5.4 (-6.6, -4.2)
	2023	12.5 (11.8, 13.3)	18.0 (16.9, 19.2)	-5.5 (-6.7, -4.3)

Note: For 2014–2019, a proxy for DSM-5 cannabis use disorder was constructed by mapping DSM-IV items to DSM-5 criteria. Due to changes in survey methodology, data from 2020 should not be compared with data from any other year. Data from 2021–2023 are only comparable with each other.

Supplemental Table 2. Prevalence of past-year daily/near daily (300 or more days) cannabis use by sex and prevalence difference (PD) stratified by age group, NSDUH 2014-2023

		Female	Male	Female-Male
		% (95% CI)	% (95% CI)	PD (95% CI)
Age 12-17	2014	0.8 (0.6, 1.1)	1.3 (1.0, 1.7)	-0.5 (-0.9, -0.1)
	2015	0.6 (0.3, 0.8)	1.3 (1.1, 1.6)	-0.8 (-1.1, -0.4)
	2016	0.8 (0.6, 1.0)	1.2 (0.8, 1.6)	-0.4 (-0.9, 0.0)
	2017	1.1 (0.8, 1.5)	0.8 (0.6, 1.1)	0.3 (-0.2, 0.7)
	2018	0.6 (0.4, 0.8)	1.4 (1.0, 1.8)	-0.8 (-1.2, -0.3)
	2019	1.0 (0.7, 1.2)	1.4 (1.0, 1.8)	-0.4 (-0.8, 0.0)
	2020	0.7 (-0.1, 1.5)	0.9 (0.2, 1.6)	-0.2 (-1.2, 0.8)
	2021	1.0 (0.6, 1.5)	1.1 (0.6, 1.6)	-0.1 (-0.7, 0.6)
	2022	1.2 (0.8, 1.7)	1.0 (0.6, 1.4)	0.2 (-0.4, 0.8)
	2023	1.4 (0.9, 1.9)	0.8 (0.5, 1.1)	0.5 (0.0, 1.1)
Age 18-25	2014	4.4 (3.6, 5.3)	8.6 (7.5, 9.7)	-4.2 (-5.5, -2.8)
	2015	4.9 (4.4, 5.5)	8.9 (7.7, 10.0)	-3.9 (-5.1, -2.7)
	2016	4.4 (3.7, 5.0)	8.3 (7.4, 9.3)	-4.0 (-4.9, -3.0)
	2017	5.5 (4.9, 6.2)	9.4 (8.6, 10.2)	-3.8 (-4.9, -2.8)
	2018	5.4 (4.6, 6.1)	9.2 (8.1, 10.2)	-3.8 (-5.0, -2.5)
	2019	5.7 (5.0, 6.5)	9.5 (8.6, 10.4)	-3.8 (-4.9, -2.7)
	2020	5.8 (4.6, 6.9)	9.5 (7.7, 11.2)	-3.7 (-5.8, -1.6)
	2021	7.5 (6.3, 8.6)	9.0 (7.6, 10.4)	-1.5 (-3.3, 0.2)
	2022	9.4 (8.3, 10.4)	10.6 (9.4, 11.9)	-1.3 (-2.7, 0.2)
	2023	7.9 (6.7, 9.1)	10.8 (9.6, 11.9)	-2.9 (-4.6, -1.1)
Age 26+	2014	1.1 (0.9, 1.2)	3.0 (2.6, 3.4)	-1.9 (-2.4, -1.5)
	2015	1.2 (1.0, 1.4)	2.6 (2.3, 3.0)	-1.4 (-1.8, -1.0)
	2016	1.3 (1.1, 1.5)	2.9 (2.5, 3.3)	-1.6 (-2.1, -1.2)
	2017	1.7 (1.5, 2.0)	3.3 (2.9, 3.7)	-1.6 (-2.0, -1.2)
	2018	1.7 (1.5, 1.9)	3.9 (3.4, 4.3)	-2.2 (-2.7, -1.7)
	2019	2.4 (2.1, 2.7)	4.3 (3.9, 4.7)	-1.9 (-2.4, -1.4)
	2020	2.9 (2.3, 3.4)	4.6 (4.0, 5.2)	-1.7 (-2.6, -0.9)
	2021	3.4 (2.9, 4.0)	5.8 (5.0, 6.5)	-2.3 (-3.2, -1.4)
	2022	3.6 (3.2, 4.0)	6.8 (5.9, 7.7)	-3.2 (-4.2, -2.2)
	2023	4.4 (3.9, 4.9)	6.8 (6.1, 7.6)	-2.5 (-3.1, -1.8)

Note: For 2014–2019, a proxy for DSM-5 cannabis use disorder was constructed by mapping DSM-IV items to DSM-5 criteria. Due to changes in survey methodology, data from 2020 should not be compared with data from any other year. Data from 2021–2023 are only comparable with each other.

Supplemental Table 3. Prevalence of DSM-5 cannabis use disorder by sex and prevalence difference (PD) stratified by age group, NSDUH 2014-2023

		Female	Male	Female-Male
		% (95% CI)	% (95% CI)	PD (95% CI)
Age 12-17	2014	3.6 (3.0, 4.2)	4.3 (3.6, 5.1)	-0.7 (-1.6, 0.2)
	2015	3.1 (2.5, 3.7)	4.0 (3.3, 4.6)	-0.8 (-1.7, 0.0)
	2016	3.1 (2.6, 3.7)	3.6 (3.0, 4.2)	-0.5 (-1.2, 0.2)
	2017	3.0 (2.6, 3.5)	3.4 (2.8, 4.0)	-0.4 (-1.1, 0.4)
	2018	3.1 (2.6, 3.6)	3.6 (2.9, 4.2)	-0.5 (-1.3, 0.4)
	2019	4.0 (3.4, 4.5)	4.7 (4.0, 5.4)	-0.7 (-1.6, 0.2)
	2020	4.2 (2.5, 5.9)	3.9 (2.6, 5.2)	0.3 (-2.1, 2.6)
	2021	5.5 (4.4, 6.6)	5.0 (3.8, 6.1)	0.6 (-0.7, 1.9)
	2022	5.8 (4.8, 6.8)	4.5 (3.9, 5.2)	1.3 (0.0, 2.5)
	2023	5.8 (5.1, 6.6)	3.4 (2.6, 4.3)	2.4 (1.4, 3.4)
Age 18-25	2014	6.6 (5.7, 7.6)	12.9 (11.8, 14.1)	-6.3 (-7.7, -4.9)
	2015	6.4 (5.7, 7.0)	12.3 (11.1, 13.5)	-6.0 (-7.3, -4.6)
	2016	6.3 (5.6, 7.0)	12.1 (11.2, 13.1)	-5.9 (-7.0, -4.8)
	2017	6.9 (6.2, 7.7)	11.8 (10.8, 12.8)	-4.9 (-6.1, -3.7)
	2018	8.2 (7.5, 9.0)	12.9 (11.6, 14.2)	-4.7 (-6.1, -3.2)
	2019	9.1 (8.1, 10.1)	12.6 (11.7, 13.6)	-3.5 (-5.0, -2.1)
	2020	11.6 (9.8, 13.4)	15.5 (13.7, 17.3)	-3.9 (-6.3, -1.5)
	2021	13.1 (11.5, 14.8)	16.4 (14.6, 18.3)	-3.3 (-5.6, -1.0)
	2022	15.6 (14.2, 16.9)	17.4 (15.8, 19.0)	-1.8 (-3.8, 0.1)
	2023	14.6 (13.3, 15.8)	18.0 (16.4, 19.6)	-3.5 (-5.8, -1.2)
Age 26+	2014	0.9 (0.6, 1.1)	2.2 (1.9, 2.5)	-1.3 (-1.7, -0.9)
	2015	0.7 (0.6, 0.8)	2.1 (1.8, 2.4)	-1.4 (-1.8, -1.1)
	2016	0.9 (0.7, 1.0)	2.1 (1.7, 2.4)	-1.2 (-1.6, -0.8)
	2017	0.8 (0.6, 0.9)	2.1 (1.8, 2.3)	-1.3 (-1.6, -1.0)
	2018	1.0 (0.8, 1.2)	2.6 (2.3, 3.0)	-1.6 (-2.0, -1.2)
	2019	1.2 (1.0, 1.4)	2.6 (2.2, 2.9)	-1.4 (-1.8, -1.0)
	2020	3.0 (2.5, 3.5)	4.8 (4.2, 5.4)	-1.8 (-2.6, -1.0)
	2021	3.3 (2.8, 3.8)	5.9 (5.2, 6.6)	-2.6 (-3.4, -1.8)
	2022	4.0 (3.5, 4.4)	7.1 (6.3, 7.9)	-3.1 (-4.0, -2.2)
	2023	4.0 (3.6, 4.4)	7.1 (6.5, 7.8)	-3.1 (-3.8, -2.5)

Note: For 2014–2019, a proxy for DSM-5 cannabis use disorder was constructed by mapping DSM-IV items to DSM-5 criteria. Due to changes in survey methodology, data from 2020 should not be compared with data from any other year. Data from 2021–2023 are only comparable with each other.

Supplemental Table 4. Estimated population counts (in thousands) by sex, age group, and cannabis use outcomes (past-month use, daily/near-daily use, and DSM-5 cannabis use disorder), NSDUH 2014–2023

		Total Population		Past-month		Daily/near daily		DSM-5 cannabis use disorder	
		Female	Male	Female	Male	Female	Male	Female	Male
Age 12-17	2014	12,193	12,682	814	990	102	169	438	546
	2015	12,208	12,685	808	944	67	169	376	497
	2016	12,215	12,682	726	844	95	154	379	449
	2017	12,238	12,705	817	816	135	108	367	425
	2018	12,218	12,677	759	866	74	175	377	448
	2019	12,223	12,682	888	977	120	180	481	589
	2020	12,259	12,724	670	784	88	120	516	499
	2021	12,731	13,288	836	736	134	146	703	659
	2022	12,567	13,159	929	667	156	135	731	597
	2023	12,661	13,255	847	717	175	111	740	454
Age 18-25	2014	17,405	17,530	2,808	4,123	770	1,504	1,150	2,254
	2015	17,380	17,527	2,883	4,120	859	1,556	1,099	2,148
	2016	17,208	17,362	2,990	4,136	757	1,449	1,070	2,093
	2017	17,069	17,237	3,199	4,206	946	1,616	1,173	2,021
	2018	16,955	17,081	3,345	4,106	911	1,563	1,382	2,182
	2019	16,830	16,903	3,566	4,156	963	1,608	1,520	2,115
	2020	16,731	16,766	3,849	3,953	967	1,587	1,942	2,595
	2021	16,735	16,724	3,805	4,444	1,251	1,507	2,201	2,748
	2022	17,298	17,488	4,276	4,805	1,620	1,859	2,690	3,040
	2023	16,965	17,069	4,028	4,333	1,338	1,836	2,468	3,078
Age 26+	2014	107,102	98,211	4,705	8,993	1,142	2,953	922	2,135
	2015	108,373	99,521	4,929	8,534	1,299	2,616	752	2,095
	2016	109,395	100,568	5,369	9,554	1,385	2,916	949	2,062
	2017	110,804	102,050	6,225	10,451	1,901	3,371	872	2,104
	2018	111,767	103,054	7,179	11,282	1,883	3,987	1,104	2,703
	2019	112,625	103,959	8,423	13,447	2,727	4,473	1,352	2,683
	2020	113,531	104,901	9,868	12,787	3,281	4,840	3,358	5,014
	2021	113,614	106,752	11,379	15,452	3,919	6,156	3,724	6,273
	2022	113,902	107,593	13,347	18,393	4,105	7,322	4,514	7,607
	2023	115,218	108,291	14,453	19,521	5,049	7,405	4,585	7,717

Note: For 2014–2019, a proxy for DSM-5 cannabis use disorder was constructed by mapping DSM-IV items to DSM-5 criteria. Due to changes in survey methodology, data from 2020 should not be compared with data from any other year. Data from 2021–2023 are only comparable with each other.